Month: September 2026

Systemic therapy for urological tumors is undergoing a profound transformation, shifting from empiric treatment toward mechanism-driven, precision-based risk stratification and whole-course management. In clear cell renal cell carcinoma (ccRCC), the immune-excluded tumor microenvironment is an important factor influencing the efficacy of immune checkpoint inhibitors. In urothelial carcinoma, antibody-drug conjugates (ADCs) combined with immunotherapy are moving beyond first-line treatment for advanced disease and increasingly being explored in the perioperative setting. For von Hippel-Lindau (VHL) syndrome, standardized management of this rare disease and the application of HIF-2α inhibitors are also reshaping traditional approaches to multi-organ intervention. As new mechanisms and therapeutic strategies continue to expand the boundaries of treatment, identifying patients most likely to benefit, dynamically evaluating treatment response, and appropriately transitioning patients with disease progression to subsequent therapies have become key questions in clinical practice. At the 2026 Pujiang Urological Oncology Academic Conference, Oncology Frontier – Urology Frontier invited Professor Hailiang Zhang of Huadong Hospital Affiliated to Fudan University for an exclusive interview. Professor Zhang discussed the mechanisms of immunotherapy resistance in renal cell carcinoma, advances in the diagnosis and treatment of urothelial carcinoma and VHL syndrome, as well as precision treatment selection and whole-course management.

The 2026 Annual Meeting of the Chinese Anti-Cancer Association (CACA) Urological Oncology Committee was held in Tianjin. The meeting brought together experts to discuss standardized diagnosis and treatment of urological cancers, multidisciplinary collaboration, and full-course cancer management. As diagnostic and therapeutic technologies continue to advance, how to truly integrate prevention, screening, diagnosis, treatment, and rehabilitation, while improving long-term patient outcomes through multidisciplinary collaboration, remains an important challenge in clinical practice. During the meeting, Oncology Frontier · UroStream invited Professor Gang Zhu of Beijing United Family Hospital for an interview. He shared his perspectives on the gaps in full-course management of urological cancers, the collaborative model of comprehensive cancer centers, and his vision for the development of the field.

With the accelerating aging of the population, health screening has been increasingly promoted across medical institutions at different levels. As a result, the early detection rates of urologic malignancies, including prostate, bladder, and kidney cancers, have improved, while standardized disease management has received growing attention. Against this backdrop, important challenges in clinical practice include how to achieve more precise diagnosis after a positive prostate cancer screening result while avoiding unnecessary biopsies and overtreatment; how to appropriately balance the clinical benefits of treatment against quality-of-life preservation in older patients; and how to strengthen the capacity of primary healthcare institutions for early detection and standardized initial diagnosis. At the 2026 academic meetings of the Chinese Anti-Cancer Association (CACA) focusing on urologic oncology, Oncology Frontier – UroStream invited Professor Yuanxin Jia from Jixi People's Hospital to share his clinical experience and perspectives on these key issues.

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai, bringing together experts from China and abroad to discuss standardized diagnosis and treatment, innovations in surgical techniques, and advances in precision medicine in urological oncology. In recent years, immunotherapy and antibody-drug conjugates (ADCs) have progressively moved from the treatment of advanced urothelial carcinoma (UC) into the perioperative setting, reshaping the overall treatment landscape of bladder cancer. Oncology Frontier – UroStream invited Professor Chunguang Ma of the Department of Urology, Fudan University Shanghai Cancer Center, for an interview to discuss changes in the landscape of adjuvant therapy for UC, the optimal timing and patient selection for adjuvant immunotherapy, future directions for ADC–immunotherapy combinations, and the integration of surgery with systemic therapy, sharing his clinical experience and perspectives on emerging developments.

From July 31 to August 2, 2026, the 2026 “Renyi” Clinical Research Conference on Innovative Anticancer Drugs was held in Nanjing. The conference was part of the academic events celebrating the 90th anniversary of Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University and Jiangsu Women and Children’s Medical Center). Under the theme “Innovating Drug Development, Driving Translational Research, Celebrating 90 Years of Medical Excellence, and Embarking on a New Journey,” the conference focused on the full development pathway of clinical research on innovative anticancer drugs.

The Northern Breast Cancer Salon was recently held successfully in Qingdao. The meeting focused on the latest advances and clinical hot topics in breast cancer, bringing together numerous experts and scholars for in-depth academic exchange. During the meeting, Professor Wenyan Chen of Nanchang People's Hospital and Professor Ning Xie of Hunan Cancer Hospital respectively shared their perspectives on “Treatment options for HER2-positive metastatic breast cancer after failure of H-based therapy — T-DXd, SHR-A1811, and others.” Following the meeting, Oncology Frontier invited the two professors to further review and elaborate on their respective perspectives, with the aim of providing clinicians with clearer insights and practical guidance on treatment selection after failure of H-based therapy.

Over the past two decades, the treatment of HER2-positive breast cancer has undergone a dramatic transformation, evolving from targeted therapy to the era of antibody-drug conjugates (ADCs), with substantial improvements in patient survival and prognosis. Recently, the Northern Breast Cancer Salon was successfully held in Qingdao. During the meeting, Oncology Frontier interviewed Professor Guohong Song of Peking University Cancer Hospital, who provided an in-depth overview of milestone developments in the treatment of HER2-positive breast cancer, individualized treatment strategies involving treatment “escalation” and “de-escalation” in early breast cancer, and the changes and future prospects brought about by ADC therapies.

Breast cancer is the most commonly diagnosed malignancy among women worldwide. Looking back over the past century, its diagnosis and treatment have evolved from viewing breast cancer primarily as a locoregional disease treated mainly with surgery, to recognizing its systemic nature and developing systemic therapies, and ultimately to the clinical adoption of molecular subtype-based treatment. Each transformation has brought significant improvements in patient survival and prognosis. Today, with continued advances in genetic testing technologies, breast cancer treatment is evolving further from molecular subtype-based approaches toward precision treatment guided by genetic alterations. Recently, the Northern Breast Cancer Salon was successfully held in Qingdao. Professor Yongmei Yin of Jiangsu Provincial People's Hospital delivered a presentation entitled “Seeing the Subtle to Foresee the Far — The Evolution of Precision Diagnosis and Treatment in Breast Cancer from Molecular Subtyping to Gene-Guided Therapy,” systematically reviewing the evolution and breakthroughs in breast cancer treatment strategies and providing an in-depth interpretation of the emerging landscape of precision therapy, from molecular subtyping to gene-driven treatment. This article summarizes the key points of her presentation, with the aim of providing reference and inspiration for clinical practice.

Recently, the Northern Breast Cancer Salon was successfully held in Qingdao, bringing together leading experts and scholars to discuss the latest advances and clinical hot topics in breast cancer. During the meeting, Professor Jin Yang of the First Affiliated Hospital of Xi'an Jiaotong University delivered a systematic and insightful presentation on controversial issues surrounding immunotherapy for advanced breast cancer. Oncology Frontier interviewed Professor Yang during the meeting to discuss current controversies in immunotherapy, key topics under consideration for the new edition of the Chinese Expert Consensus on the Clinical Application of Immunotherapy for Breast Cancer, and the challenges of translating these recommendations into clinical practice.